Xylyx Bio
Xylyx Bio: Enhancing drug discovery with science-based solutions, saving time and money.
Founded
2016Xylyx Bio: Enhancing drug discovery with science-based solutions, saving time and money.
Founded with the mission to revolutionize drug discovery and regenerative medicine, Xylyx Bio focuses on providing science-based solutions through its platform technology of tissue-specific ECM substrates, clinically relevant data packages, and compound testing services. The company aims to increase predictiveness and inform better decision-making in drug discovery, ultimately saving time and money in the development of lifesaving drugs. Xylyx Bio's products include Inspirex™ Lung and Liver Organ Recovery, Matrikynes® Tissue Regeneration, and In Matrico® Kits & Assays, targeting the pharmaceutical and biotech markets.
Notable affiliated individuals include experts in tissue engineering and regenerative medicine, contributing to the company's innovative approach. Xylyx Bio has garnered attention from investors focused on cutting-edge biomedical technologies. Key achievements include the successful development and commercialization of their Inspirex™ and Matrikynes® product lines, which have significantly impacted the efficiency of drug discovery processes. Overall, Xylyx Bio's contributions are advancing the field of regenerative medicine and enhancing the predictiveness of preclinical drug testing.
Companies similar to Xylyx Bio include Sylvatica Biotech, LyGenesis, BioXyTran and X-Therma.
Xylyx Bio was founded in 2016.
Xylyx Bio's headquarters is located in New York, US.
Xylyx Bio's most recent funding round was for $2.2M (USD) in September 2021.
As of Sep 2, 2021, Xylyx Bio has disclosed funding of $2.4M (USD). Undisclosed round amounts are excluded.
Xylyx Bio has 17 employees as of Feb 4, 2024.
X-Therma
x-therma.com
